Difference between revisions of "Trastuzumab-dkst (Ogivri)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex") |
||
| (10 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
<br>Extravasation: [[neutral]] | <br>Extravasation: [[neutral]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. |
| − | ==Diseases for which it is | + | ==Diseases for which it is established== |
| − | *[[Breast_cancer, | + | *[[Breast_cancer,_HER2-positive|HER2+ breast cancer]] |
*[[Esophageal cancer|HER2+ esophageal cancer]] | *[[Esophageal cancer|HER2+ esophageal cancer]] | ||
*[[Gastric cancer|HER2+ gastric cancer]] | *[[Gastric cancer|HER2+ gastric cancer]] | ||
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *12 | + | *2017-12-01: Initial approval for the treatment of patients with [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|overexpressing]] [[Breast_cancer|breast]] or metastatic [[Gastric cancer|stomach cancer (gastric or gastroesophageal junction adenocarcinoma)]]. ''(Based on HERITAGE)'' |
| − | [[Category: | + | ==Also known as== |
| + | *'''Brand name:''' Ogivri | ||
| + | |||
| + | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Protein expression-specific medications]] | [[Category:Protein expression-specific medications]] | ||
| − | + | ||
[[Category:Anti-HER2 antibodies]] | [[Category:Anti-HER2 antibodies]] | ||
| − | [[Category:Neutral | + | [[Category:Neutral]] |
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
| Line 30: | Line 33: | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2017]] |
[[Category:Biosimilars]] | [[Category:Biosimilars]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 01:48, 29 June 2024
Note: this is the second FDA-approved biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.
General information
Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is established
Patient drug information
To be completed
History of changes in FDA indication
- 2017-12-01: Initial approval for the treatment of patients with HER2-overexpressing breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma). (Based on HERITAGE)
Also known as
- Brand name: Ogivri